CDK1 and cancer: We have earlier reported NSC777201 for some biological activities [25,26,67], herein, we used a molecular docking approach and an NCI’s ovarian cancer cell lines to evaluate its anti-cancer activity and explore its possibility for targeting TTK, NEK2, and CDK1.